News >

Expert Discusses Lymphedema Treatment and Challenges in Breast Cancer

Brandon Scalea
Published: Tuesday, Dec 18, 2018

Oscar J. Manrique, MD

Oscar J. Manrique, MD

Lymphedema remains an incurable adverse event that is sometimes developed by patients with breast cancer who have undergone surgery or received radiation therapy for their malignancy; however, outcomes can be improved if the condition is diagnosed and managed in its early stages, said Oscar J. Manrique, MD.

State of the Science Summit™ on Breast Cancer, Manrique discussed the current treatments for patients with lymphedema who have breast cancer and the challenges that remain in this space.

OncLive: How frequently does lymphedema occur in patients with breast cancer?

Manrique: [The frequency of this condition] varies [in this patient population]. It definitely depends on different factors, such as radiation, or if the patient requires an axillary lymph node dissection. I would say that in a patient with these risk factors, it occurs about 30% to 40% of the time.

What is the current approach for treating these patients?

Our goal is to intervene early and do what are called physiological procedures. Even now, we are trying to do prophylactic bypasses during axillary lymph node dissection with reverse mapping. We identify the lymphatics that are leaking and try to connect them with a vein. Most of the time, the patients that I see are the ones who already have lymphedema, so most of these procedures are palliative.

There is still no cure for patients with lymphedema, but hopefully, we can see that in the next several years. One thing we are seeing now, however, is an improvement in outcomes, particularly in quality of life.

How do you determine the best treatment approach for a patient?

The key is to intervene early. Our goal is to perform these physiological procedures because they are easier and require microsurgical techniques. These procedures can be challenging, but someone who is trained in microsurgery should be able to perform them. We do not want to let lymphedema elevate to a higher stage because that is when the condition becomes very difficult to treat.

What is the biggest challenge?

It is probably patient selection because that is our key to success. Not every patient who comes to see you with questionable lymphedema [actually] has lymphedema. As I mentioned, the condition it is not curative, but we still want to see a good outcome.

What is needed to overcome this challenge?

A multidisciplinary approach is needed. That is one of the great things about Mayo Clinic; we work in combination with the oncologists, breast surgeons, physical therapists—you name it. When we see our patients, we get involved [in the early stages]. We have algorithms to help us decide which approach to use as soon as possible. We need to be more conscious about this chronic disease. It is something we have known about for a long time, but sometimes people ignore it and don't realize how difficult it makes for patients to live normal, daily lives. These patients deal with pain, infection of their limbs, and worsening of symptoms.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication